Contingency valuation and preferences of health states associated with side effects of antipsychotic medications in schizophrenia

Schizophrenia Bulletin

Volumn 27, Issue 4, 2001, Pages 643-651

  Sevy, Serge ^a   Nathanson, Kay ^a   Schechter, Clyde ^a   Fulop, George ^a  

^a ZUCKER HILLSIDE HOSPITAL   (United States)

Author keywords

Antipsychotics; Schizophrenia; Side effects; Standard gamble; Utility; Willingness to pay

Indexed keywords

NEUROLEPTIC AGENT;

ADULT; AKINESIA; ARTICLE; CONSTIPATION; DYSTONIA; DYSURIA; HEADACHE; HUMAN; IMPOTENCE; MAJOR CLINICAL STUDY; ORTHOSTATIC HYPOTENSION; POLYURIA; PRIORITY JOURNAL; SCHIZOPHRENIA; SKIN DISEASE; SLEEP DISORDER; TARDIVE DYSKINESIA; TREMOR; VISUAL IMPAIRMENT; XEROSTOMIA;

EID: 0035697010     PISSN: 05867614     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.schbul.a006903     Document Type: Article

References (34)

1. Measuring the monetary value of lifesaving programs
2. Quality of life of schizophrenic patients on medications and implications for new drug trials
3. The use of atypical antipsychotics in the management of schizophrenia
4. Measuring heart patients' willingness to pay for changes in angina symptoms
5. Economic and health state utility determinations for schizophrenic patients treated with risperidone or haloperidol
6. Can clients with schizophrenia describe feelings and beliefs about taking medications?
7. Willingness to pay for publicly-provided goods: A possible measure of benefits?
8. Incorporating utility-based quality-of-life assessment measures in clinical trials: Two examples
9. Subjective utility ratings of neuroleptics in treating schizophrenia
10. Willingness to pay for probabilistic improvements in health status: A psychological perspective
11. Mini-Mental State: A practical method for grading the cognitive state of patients for the clinician
12. Olanzapine: A pharmacoeconomic review of its use in schizophrenia
13. Contingent valuation of supplemental health care in Israel
14. A self-report scale predictive of drug compliance in schizophrenic patients: Reliability and discriminative ability
15. The contingent-valuation method
16. Willingness to pay for reductions in angina pectoris attacks
17. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia
18. Utility, decision, and quality of life
19. Measurement of the validity of utility elicitations performed by computerized interview
20. Efficacy and extrapyramidal side effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo: A meta-analysis of randomized controlled trials
21. The side effects of antipsychotic drugs and patients' quality of life: Patient education and utility assessment with computers and multimedia
22. Willingness to pay for reduction in fatality risk: An exploratory survey
23. When do the "dollars" make sense? Toward a conceptual framework for contingent valuation studies in health care
24. Willingness to pay: A valid and reliable measure of health state preference?
25. Preferences for schizophrenia-related health states: A comparison of patients, caregivers and psychiatrists
26. Cost-benefit analysis
27. Measuring the outcome of care
28. Willingness to pay and accept risks to cure chronic disease
29. Feasibility of willingness to pay measurement in chronic arthritis
30. Measurement of health state utilities for economic appraisal: A review